1 / 19

Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis

Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis. JM Wardlaw, V Murray, PAG Sandercock. University of Edinburgh and Karolinska Institutet, Stockholm. Brenda Thomas, Greg del Zoppo, Eivind Berge, Take Yamaguchi. Thrombolysis Systematic Review.

roxannebeal
Download Presentation

Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska Institutet, Stockholm Brenda Thomas,Greg del Zoppo, Eivind Berge, Take Yamaguchi

  2. Thrombolysis Systematic Review • Continuously updated since 1990 • All randomised controlled trials of any thrombolytic drug versus control • Last update 2003: • 18 trials (n=5675) • Drugs: rt-PA, streptokinase, uro-kinase, rPro-urokinase, • Time windows: 0-3, 0-6 hrs • Brain Imaging : CT • Age over 80 : 42 patients

  3. Methods • Material • New trials • New data from existing trials • Methods • Multiple overlapping ascertainment methods • Two independent reviewers extracted data • Odds Ratios (ORs), 95% CI, heterogeneity • Metaregression on some key variables

  4. Methods – data sought Previous outcomes : • Intracranial haemorrhage - asymptomatic, symptomatic and fatal • Death early and late, • Poor functional outcome • Infarct early swelling, Previous subgroups : • Time to treatment, • antithrombotic treatment, • stroke severity, • mRS cut point, New subgroups : • type of imaging, CT or MR • CT infarct signs, • stroke subtype, large artery/lacunar

  5. What’s new in 2008? 2008: • 8 new trials (n=+1477, total: n=7152) • Drugs: 3 rt-PA; 2 UK; 3 desmoteplase • Route: 2 intra-arterial, 6 intravenous • Time windows: 0-6, 3-4.5, 3-9, 0-24 hrs • Imaging pre randomisation: • CT: 5 • MR: 3 (+1) DWI/PWI mismatch • Age over 80: ≈42

  6. 0.91 (0.64, 1.42) 0.94 (0.72, 1.24) 0.77 (0.47, 0.89) 1.09 (0.49, 1.72) 0.55 (0.31, 1.00) 0.57 (0.28, 1.14) 0.85 (0.53, 1.38) 0.82 (0.73, 0.91) Death or dependency at the end of follow-up IV urokinase IV streptokinase IV rt-PA IV streptokinase + aspirin IA pro-urokinase IA urokinase IV desmoteplase Total

  7. ECASS 3 Inclusion: 3-4.5 hours Age 18-80 yrs Excluded : NIHSS>25 or CT infarct signs >1/3MCA diabetes and prior stroke stroke in previous 3 months Outcomes: SICH: “any apparently extravascular blood in the brain or within the cranium that was associated with clinical deterioration, as defined by an increase of 4 points or more in the score on the NIHSS, or that led to death and that was identified as the predominant cause of the neurologic deterioration” Good functional outcome: mRS 0-1 vs 2-6

  8. ECASS 3 Baseline imbalances rt-PA PLA P Age 64.9 65.6 0.36 NIHSS 10.7 11.6 0.03 9 10 Diabetes 14.8 16.6 0.47 Prior 7.7 14.1 0.03 stroke

  9. All drugs and rt-PA Summary of effects, 2008; ORs (95% CI) SICH Late Death or (incl fatal)DeathDependency All drugs 3.3 1.3 * 0.8 * n=7152 2.7 - 4.1 1.1 - 1.5 0.7 - 0.9 p<0.00001 p=0.06 p<0.0001 rt-PA 3.11.1 0.8 * n=3977 2.3 - 4.0 1.0 - 1.4 0.7 - 0.9 p<0.00001 p=0.16 p<0.0001 * Significant heterogeneity confounds interpretation

  10. rt-PA trials: 2003 versus 2008 ORs (95% CI) SICH Late Death or (incl fatal) DeathDependency 20033.1 1.2 * 0.8 * n=2955 2.3 - 4.2 0.9 - 1.5 0.7 - 0.9 p<0.00001 p=0.14 p=0.003 2008 3.11.1 0.8 * n=3977 2.3 - 4.0 1.0 - 1.4 0.7 - 0.9 p<0.00001 p=0.16 p<0.0001 * significant heterogeneity confounds interpretation

  11. rt-PA trials: 2008 N per 1000 treated, 95% CI Outcome all 0-3 hrs 3-6 hrs SICH 60 70 60 50, 80 40, 100 50, 80 Death100 20 10,40 50, 50 0, 50 Death or60 110 40 Depend. 100, 30 170, 50 80, 10 X = decrease X = increase

  12. mRS 2-6 or 3-6 (rt-PA): Similar overall result IV tPA vs control Mori NINDS ECASS ECASS 2 ECASS 3 Atlantis A Atlantis B rt-PA subtotal 2 to 6 Modified Rankin: 3 to 6 0.1 0.78 1 5 10 0.1 0.77 1 5 10 thrombolysis worse thrombolysis better CDSR Oct 2004

  13. 0.1 0.2 0.5 1 2 5 10 favours treatment favours control Death or dependency: subgroups OR (95% CI) n Trials n patients Latest time to treatment, all drugs (hours) 3 1 624 4.5 2 1161 6 9 3463 9 3 325 0.62 (0.45, 0.85) 0.85 (0.68, 1.07 0.84 (0.73, 0.96) 0.85 (0.52, 1.39) Treatment time rt-PA (hours) 0.64 (0.5. 0.8) 0.83 (0.7, 0.9) 0-3 5 930 3-6 6 2766

  14. 0.1 0.2 0.5 1 2 5 10 favours treatment favours control Subgroups : Imaging (all drugs, all times) OR (95% CI) n Trials n patients Death or dependency 0.79 (0.8, 0.9) CT 10 4808 0.87 (0.6, 1.3) MR DWI/PWI 4 425 SICH CT MR DWI/PWI 4.55 (3.31, 6.27) 7.51 (1.39, 40.54) Death 1.18 (1.01, 1.40) 2.18 (1.09, 4.36) CT MR DWI/PWI

  15. Other results, 2008 CT infarct signs and thrombolysis (3 trials): no clear interaction Infarct swelling (5 trials): reduced with rt-PA (OR 0.78, 0.62, 1.00, p=0.05) Metaregression on • Time to treatment (2 methods) • Antithrombotic therapy • Selection by MR DWI/PWI vs CT • ”Stroke severity” (2 methods) • Dose – MI equivalent vs ”stroke” dose • Trial size did not explain differences between trials

  16. Conclusion, Update 2008 • Heterogeneity still confounds interpretation • ECASS 3 consistent with existing rt-PA meta-analysis. • Potential for benefit to at least six hours • Limited new knowledge on latest time windows. • Almost complete lack of data on older patients; antithrombotic use; stroke severity/subtype, diabetes • Outcome following selection on MR mismatch not apparently different to CT. • No material change in main outcomes since 2003.

  17. Implications • Further data on i.v. rt-PA needed from randomised trials : • Out to at least six hours • Older patients, diabetes, hypertension, stroke subtypes • Clarifying risk factors for haemorrhage and death

  18. Competing interests • SITS-MOST Steering and CT adjudication • ECASS 3 CT reading Committee • IST3 Trial Steering Committee and Imaging lead

  19. rt-PA 2008- OR and events per 1000 treated rt-PA Effect per 1000 Symptomatic ICH : <3 hrs +70 3-6 hrs +60 Death by three months : <3 hrs 0 +20 3-6 hrs Dead or Dependent : <3 hours -110 - 40 3-6 hours 0.1 0.66 0.84 1.0 1.333.37 10 OR better thrombolysis worse CDSR 2008

More Related